Nac (Acetylcysteine)

Acetylcysteine supplies cysteine, a precursor for glutathione, boosting cellular antioxidant defenses. It also cleaves disulfide bonds in mucus glycoproteins, decreasing viscosity and enabling easier clearance from the airways. These combined actions support its mucolytic and hepatoprotective effects.

The appropriate dose of Nac is set by the prescribing clinician based on the specific indication, patient age, weight, renal function and severity of the condition. Dosage regimens can differ for oral, buccal or intravenous routes, and the prescriber will tailor therapy accordingly.

Safety data for acetylcysteine in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against uncertain risks and discuss options with the patient. If treatment is deemed necessary, it should be administered under close medical supervision.

To request Nac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Compared with agents such as carbocysteine or ambroxol, acetylcysteine has a dual role as both a mucolytic and an antioxidant, making it useful for liver protection in overdose scenarios. Its mechanism of breaking disulfide bonds is distinct, and it is often preferred when both mucus thinning and glutathione replenishment are desired.

Nac should be stored below 25 °C in its original container, protected from moisture and direct sunlight. Maintaining a stable ambient temperature helps preserve its chemical stability and ensures consistent efficacy.

Nac can be given orally as a solution or tablet, buccally as a lozenge, or applied cutaneously depending on the formulation. The route is selected by the prescriber according to the clinical indication, and administration instructions are provided with the product label.

Serious adverse events include anaphylactic reactions, severe skin disorders such as Stevens‑Johnson syndrome, bronchospasm in susceptible individuals, marked hypotension after rapid intravenous infusion, and significant elevations in liver enzymes. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to acetylcysteine or any excipients in the formulation should avoid Nac. Caution is also advised for individuals with severe asthma, uncontrolled renal impairment, or those receiving nitroglycerin, as the combination may precipitate adverse effects.